For the Inventor, By the Inventor

Enter assignee name

San Diego, CA, United States of America

Canji Inc.

USPTO Granted Patents = 42

% Expired Patents = 33.3

EPO Patents = 6

Forward Citations = 510

Loading Chart...

Loading Chart...

52 inventors (with patents filed for the assignee):

Daniel C Maneval (9 out of 12 patents)

Heidrun Engler (8 out of 8 patents)

Richard J Gregory (8 out of 24 patents)

4. Paul W Shabram (7 out of 8 patents)

5. H Michael Shepard (5 out of 60 patents)

6. Tattanahalli L Nagabhushan (5 out of 30 patents)

7. Ken N Wills (5 out of 5 patents)

8. Stephen Kenneth Youngster (5 out of 6 patents)

9. Muralidhara Ramachandra (4 out of 4 patents)

10. Monica Zepeda (3 out of 4 patents)

11. Drake M LaFace (3 out of 3 patents)

12. Douglas Antelman (3 out of 3 patents)

13. Kenneth N Wills (3 out of 3 patents)

14. Wen-Hwa Lee (2 out of 21 patents)

15. Timothy P Mayall (2 out of 3 patents)

Core Competencies:

Adenoviral Expression Vectors

Nucleic Acid Delivery

Viral Vectors

Cancer Treatment

Transfection Agents

Retinoblastoma Fusion Proteins

Therapeutic Use

Gene Expression Regulation

Tumor Suppressor Genes

Stem Cell Products

Ocular Diseases

Immune Response Reduction

42 patents: Sort by Forward Citations

1. 8398968 - Adenoviral expression vectors (2013-03-19),

2. 8329671 - Reduction of dermal scarring (2012-12-11),

3. 8133481 - Selectively replicating viral vectors (2012-03-13),

4. 8022044 - Compositions and methods for therapeutic use (2011-09-20),

5. 7691822 - Methods and compositions for treatment of interferon-resistant tumors (2010-04-06),

6. 7691370 - Selectivity replicating viral vector (2010-04-06),

7. 7538093 - Compositions and methods for therapeutic use (2009-05-26),

8. 7534769 - Compositions and methods for enhancing delivery of therapeutic agents to cells (2009-05-19),

9. 7465442 - Reduction of dermal scarring (2008-12-16),

10. 7462351 - Nucleic acid delivery (2008-12-09),

11. 7355056 - Transfection agents (2008-04-08),

12. 7307146 - DNAXCCR10 (2007-12-11),

13. 7157261 - Rat secreted embryonic alkaline phosphatase (2007-01-02),

14. 7157079 - Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms (2007-01-02),

15. 7105156 - Method of using an adenoviral vector encoding a retinoblastoma protein to treat hyperproliferating cells (2006-09-12),

Company Overview

Canji Inc., based in San Diego, CA, specializes in the development of advanced gene therapy solutions utilizing adenoviral expression vectors and viral vectors for effective nucleic acid delivery. The company focuses on innovative therapeutic agents aimed at reducing immune responses, particularly in the context of tumor suppressor genes and retinoblastoma proteins. Through its cutting-edge research, Canji Inc. is dedicated to advancing the field of gene therapy, contributing to transformative treatments for various genetic disorders and cancers.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

42 Patents

#147 in San Diego, CA

#1,941 in California

#8,258 in US

#16,354 in the World

San Diego, CA, United States of America

Canji Inc.

Forward Citations = 510

52 inventors:

Daniel C Maneval (9 out of 12 patents)

Heidrun Engler (8 out of 8 patents)

Richard J Gregory (8 out of 24 patents)

4. Paul W Shabram (7 out of 8 patents)

5. H Michael Shepard (5 out of 60 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Canji Inc.. Retrieved from https://idiyas.com/company/canji

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…